INSTITUTE FOR RADIOELEMENTS YOUR SUCCESS IS OUR PASSION EXCELLENCE DEDICATED TO NUCLEAR MEDICINE, HEALTHCARE & ENVIRONMENT

Similar documents
Ge / 68 Ga GENERATOR* HOW TO DO PET AS SIMPLY AS SPECT? EXCELLENCE DEDICATED TO NUCLEAR MEDICINE, HEALTHCARE & ENVIRONMENT

Radiopharmaceuticals: Production and Availability

IRE ELiT. 6 th Symposium on Medical Isotopes Mechelen, 11 May Philippe van Put IRE ELiT. Ge/ 68 Ga generator: first evaluation

ENSURING RELIABLE MEDICAL ISOTOPE SUPPLY

A Billion Curies and Counting 50 years of Canadian nuclear innovation in healthcare

NEA Workshop on the Management of Non-Nuclear Radioactive Waste

Medical isotopes. in a European context. Global importance and opportunities for the Netherlands.

Radiopharmaceuticals overview of requirements

-Nuclear Energyas a key component of a viable SDG-vision. David Kock Necsa

port and maritime radiological

Cyclotron & Medical Isotopes Best Theratronics announces plans to address the medical isotope shortage by manufacturing a range of cyclotrons

Perma-Fix Medical. Investor Presentation January 2016

Nuclear Medicine Solutions

Current Market Dynamics and Future Vision of the Care Cycle

Challenges of the regulatory body in implementing the legislations for the radiopharmaceuticals: efforts of IAEA

Radiation Technology for Industries, the Role of IAEA

Valuing Healthcare Biotechnology in Europe: EuropaBio s perspective

IAEA assistance in RI production and supply: 99 Mo case

Lead the way. Molecular Imaging. GE Healthcare. imagination at work

// SAFE AND INNOVATIVE SOLUTIONS FOR THE TRANSPORT, STORAGE AND DISPOSAL OF RADIOACTIVE MATERIALS

INSTITUTE OF BIOMEDICAL SCIENCE

learning and development success

Australia s unique leadership role

Controlled dosimetry Fast and accurate process Versatile and easy to use Robust and reliable Meets the highest standards

Radioisotopes production technology -EGYPT experience

Molecular Imaging: Definition, Overview and Goals

NUCLEAR MEDICINE SUMMARY AND TABLE OF CONTENTS WORLD MARKET REPORT & DIRECTORY EDITION 2017

HELPING DELIVER LIFE-CHANGING THERAPIES HEMATOLOGY ONCOLOGY

New Ways to Source Innovation in the Healthcare Industry In-licensing needs Oncology of Janssen/Johnson & Johnson Innovation

TECHNOLOGICAL RESEARCH INSTITUTE FOR A COMPREHENSIVE AND PERSONALIZED MANAGEMENT OF INFECTIOUS DISEASES

REPORT FROM THE COMMISSION TO THE COUNCIL AND THE EUROPEAN PARLIAMENT. Operation of the High Flux Reactor in the years {SWD(2018) 46 final}

LIGHTNING PROTECTION DIVISION

LUTETIUM 177 BROAD PRODUCTION CAPABILITIES ARE EXPECTED TO STIMULATE CLINICAL APPLICATIONS OF THIS IMPORTANT THERAPEUTIC RADIOISOTOPE

SIXTH Meeting of the Arab Regulatory Bodies

The Path Ahead. Scientific Forum IAEA General Conference Vienna; 2015 Sept

International Workshop on Sustainable Management of Disused Sealed Radioactive Sources Lisbon- Portugal October 2010 Lebanon

Status of Mo-99 Supply and New Developments

2 / 1. SUMMARY public, should be well documented, and should be reviewed on a regular basis to determine whether it continues to meet the operational

MEDICAL RADIOACTIVE WASTE MANAGEMENT IN SAUDI ARABIA

Safety and Security of Supply of Medical Isotope Production

Regulatory aspects: Radiopharmacy (GMP)

Guiding Principles on Access to Healthcare. A Project of the BSR Healthcare Working Group

23 September Mr. President, Distinguished Delegates, Ladies and Gentlemen,

World status on reactor and cyclotron radioisotope production

TC cycle Regional TC Projects, Europe Division

RADIOISOTOPES in MEDICINE:

Trends for medical devices

Personalized. Health in Canada

Partnering & Networks

Progress Report. Jouko Karvinen CEO of Medical Systems

FORM 5 University of California, Davis Health System Health Physics Office HUMAN RADIATION USE RESEARCH APPLICATION

in94070.txt at Page 1 of 5 2/24/00

Vision and Strategic Research Agenda

M. Marengo DEFINING QUALITY: A BRIEF SUMMARY OF THE TERMINOLOGY. Medical Physics Department S.Orsola Malpighi University Hospital, Bologna, Italy

Mark Ramsay BEng MSc MSRP, CRadP

MINIMIZATION AND SEGREGATION OF RADIOACTIVE WASTES IAEA, VIENNA, 1992 IAEA-TECDOC-652 ISSN

Staffing - Medical Devices

An Industry Approach to Sealed Source Management at the End of Useful Life 8440

Business Transformations

The Journey of Continuous Improvement in the Reliability and Availability of the OPAL Reactor

KLINGER GROUP At a glance.

Imaging Systems. Gene Saragnese CEO Imaging Systems

Regional or Global Molybdenum-99 Supply Indian Perspective

Your Complete Quality Solution Provider for the Life Science Industry

Technology Platforms: Central Concept

Belgian class II nuclear facilities such as irradiators and accelerators: Regulatory Body attention points and operating experience feedback.

UNDERSTANDING RADIATION. Its Effects and Benefits

Statement by Dr. Sekhar Basu Chairman, Atomic Energy Commission and Secretary, Department of Atomic Energy

Information and resources for African Americans living with multiple myeloma and their caregivers

Roche in Australia Innovation Leader

A commitment to excellence in Non-Destructive Testing & Inspection through to Integrity Management

Production of radiopharmaceuticals for clinical and research uses

INTERFACE OF NUCLEAR AND BIOTECHNOLOGIES

Radioactive Substances Act 1993 The Environmental Permitting (England and Wales) (Amendment) Regulations 2011

The medical isotope crisis

A main application of tungsten alloy products, tungsten alloy radiation containers are widely applied in medical and nuclear industries.

Robert Posgai Director of Materials Procurement, Biogen (BPOG)

Novel nuclear medicine to advance patient care

Implementing the EU Food and Drink Industry s Ambition for Growth and Jobs

ARCAL REGIONAL STRATEGIC PROFILE FOR LATIN AMERICA AND THE CARIBBEAN EXECUTIVE SUMMARY

Grindeks years of growth

HEU MINIMISATION CHALLENGES. THE SUPPLY OF THE MEDICAL ISOTOPE 99-MOLYBDENUM/99m- TECHNETIUM

Radiation and Radiological Protection. Guidelines for Primary And Secondary Schools

Role Profile OPERATIONS MANAGER

Services. For seamless operations along your production line from start to finish

THE MADDOC PROMISE. Together with a superior product, our value-added solutions will address the needs of lubricant manufacturers, such as:

US Regulatory Requirements: Clinical & Clinical Research Production, SPECT & PET Radiopharmaceuticals (RPs)

Radioactive Waste Management Agency. and. Nuclear Safety Authority. in Belgium

Almac Overview.

PAREXEL ACCESS MANAGED ACCESS PROGRAMS

The Critical Need for Nuclear Medicine Radioisotopes and Research

Transport for Life. Call for action to sustain the transport of radioactive material

RADIATION What You Need To Know UNIVERSITY OF ARKANSAS OFFICE OF ENVIRONMENTAL HEALTH AND SAFETY

With Our Business Partners

Application Pack. Director of Fundraising

INGÉNIEURS CONSTRUCTEURS DEPUIS 1830

April 7, Dear Ms Närhi,

Global Threat Reduction Initiative

Guideline on core SmPC and Package Leaflet for ( 68 Ge/ 68 Ga) generator

EUROPE REGIONAL PROFILE

Transcription:

INSTITUTE FOR RADIOELEMENTS YOUR SUCCESS IS OUR PASSION EXCELLENCE DEDICATED TO NUCLEAR MEDICINE, HEALTHCARE & ENVIRONMENT

Our performance in terms of quality, reliability and safety, unprecedented in the industry, makes us the most reliable source for the supply of high-quality radioisotopes for medical use. The unique diversity of our supply chain and the outstanding commitment and skills of our employees have proven to be the key factors of our performance, particularly when it comes to patient safety and supply security of these medical radioisotopes worldwide. For many consecutive years, we have run our production operations successfully and without interruption, 24 hours a day, 365 days a year, to secure your supply and benefit the health of your patients. We are pleased to share our performance with you and help you to succeed. YOUR SUCCESS IS OUR PASSION. OUR STRENGTHS FOR YOUR SUCCESS 1. Multiple research reactors 2. Very well connected to international airports 3. On-site transport company 4. Committed employees

OUR PRODUCTS 99 Mo One of the most important radioelements produced on our site is molybdenum-99, the parent isotope of metastable technetium-99. In combination with a specific molecule, this isotope can reach the target organ and be visualized by a detection system to allow medical specialists to make reliable diagnoses. Metastable technetium-99 Close to 80% of nuclear medicine diagnoses are made using metastable technetium-99. This substance is used in many types of scanning to provide images of the metabolism of various organs such as the heart, bones, lungs, thyroid, brain, kidneys, the gastro-intestinal system, etc. This technique enables medical specialists to make reliable diagnoses in the case of many diseases such as cancers, infarctions, infections and inflammations, respiratory conditions, degenerative diseases such as Alzheimer s, and endocrine disorders. In the case of cancer, the main purpose of this type of metabolic activity imaging is to determine the extent of the disease. OUR RADIOCHEMICAL PRODUCTS 131 I and 90 Y The radioelements we produce are also used for therapeutic purposes. Radiotherapy involves selectively irradiating tumour targets (such as bones, certain organs, cells, etc.) to significantly improve the symptoms of the disease and can even increase patient survival rates. Iodine-131 The properties of iodine-131 make it more suitable for therapy than diagnosis. It is mainly used in the treatment of thyroid cancer and certain forms of hyperthyroidism. In combination with specific molecules, it is also used for the treatment of other cancers. Yttrium-90 In combination with an antibody, yttrium-90 effectively fights so-called non-hodgkin s cancers, which spread in the immune system. This product has been approved by the pharmaceutical authorities in the USA, Europe and Japan. Yttrium-90 is also used in medical devices, where, attached to particles that create embolisation of the liver blood vessels, it irradiates the surrounding cancer cells. For more information email at info@ire.eu

In order to get closer to patients needs and strengthen our international role as a major player in nuclear medicine, IRE ELiT provides solutions that meet the quality requirements for radiopharmaceutical products and can be directly administered to patients by specialized practitioners for the diagnosis or treatment of diseases. The extension of our product portfolio is supported by our R&D team and several partners with expertise in different complementary sectors. Our teams are resolutely engaged in research programmes with several universities and research centers, both in Europe and in other continents. This policy of cooperation between industry and academia constitutes a key factor for future developments in the field of cutting-edge radiopharmaceuticals. Our ambition is to provide you promising solutions for your patients. YOUR SUCCESS IS OUR PASSION. OUR STRENGHTS FOR YOUR SUCCESS 1. Stable supply chain 2. High-quality products 3. Skilled employees

OUR PRODUCTS Rheni Eo, 188 W/ 188 Re generator: a beneficial and cost-effective therapeutic solution The latest developments in the use of rhenium-188 relate to cancer therapy (liver, brain, etc.), palliative care for bone pain caused by spreading breast, lung and prostate cancer, the treatment of synovitis and cardiology. Rhenium-188 is produced using a generator that allows simplified logistics and flexibility of use ( dose on request ). Tungsten-188, the parent radioisotope of rhenium-188, with a half-life of 70 days, allows the generator to be used for several months. Additionally, the generator is linked to a concentration unit that extends the useful life by a factor of 2 to 3. This type of generator, with the concentration unit system, represents a beneficial therapeutic solution that makes it possible to considerably reduce the cost per dose. Yttri Eo, 90 Y solution : one patient, one dose Yttrium-90 can be used to effectively fight certain lymphomas (non- Hodgkin lymphomas), which are cancers that begin in the immune system (lymphocytes). Yttrium-90 in combination with specific molecules is also used for the treatment of liver cancer. Yttrium-90 comes the form of a sterile and non-pyrogenic solution. The level of activity is calibrated according to the users needs. OUR RADIOPHARMACEUTICAL PRODUCTS Galli Eo, 68 Ge / 68 Ga generator: a simple and innovative diagnostic solution Today many tracers for diagnostic imaging PET (positron emission tomography) use the Fluor-18, a radioisotope with short half-life, produced in a cyclotron near the medical examinations, which requires a long and heavy material and financial investment. Gallium-68 is another radioisotope equally favorable for PET imaging with physical characteristics similar to Fluor-18, its half-life is also very short but it has the advantage of being obtained more easily and at lower cost through a generator Germanium-68 / Gallium-68 used directly in the radiopharmacy. To facilitate the preparation of radiopharmaceuticals using Gallium-68 without compromising the safety of operators and patients, the Galli Eo generator produced by IRE ELiT is a fully integrated, closed system to get rapidly highly concentrated and very pure preparations minimizing loss of activity. The design quite innovative limits the risk of error and contamination. Finally, this generator can be used manually or connected to a synthesis module. This optimal system for using labeling kit with Gallium-68 will probably enable, thanks to imaging, a better management of cancer (neuroendocrine cancers, prostate cancer...) and other infectious diseases. RADIOPHARMACEUTICAL PRODUCTS FROM DIAGNOSIS TO THERAPEUTICS For more information, consult our specific products brochure or email at radiopharmaceutical@ire-elit.eu EXCELLENCE DEDICATED TO NUCLEAR MEDICINE, HEALTHCARE & ENVIRONMENT Galli Eo is a trademark of IRE ELiT

IRE ELiT also provides a range of high-quality services: Radioactivity analysis and radiological monitoring systems dealing with humans and environment protection; Radiological characterization of waste and facilities; Consulting and technical services in a wide variety of activities in the radiation and nuclear fields; Dismantling of radioactive sealed sources. For each of these competences, exchange and proximity to the customer is at the heart of our partnership vision. YOUR SUCCESS IS OUR PASSION. OUR STRENGHTS FOR YOUR SUCCESS 1. Reliability of the results provided 2. Flexibility in your request 3. Responsible employees

OUR SERVICES Radioactivity analysis Our laboratory is specialized in the analysis (identification and quantification) of radioactivity on a wide variety of sample types. Environment Drinking water Biological samples Food chain NORM We have equipment, infrastructures and qualified personnel that enable us to measure low-activity samples in optimal conditions. Our analytical methods are ISO 17025 accredited. Our laboratories have ISO 14001 certification, testifying to our environmental commitment. We are also a member of the ALMERA (Analytical Laboratories for the Measurement of Environmental Radioactivity) network, established and coordinated by the IAEA. OUR SERVICES Using our expertise in environmental radiological monitoring, we also develop automatic sampling and radiation monitoring systems (liquid and gaseous effluents). We manufacture highly efficient equipment for the continuous measurement of radioactivity in the environment (water and air). Radiological characterization Our Service of Radiological Characterization offers a customized service for the characterization of radioactive waste and contaminated items by gamma spectrometry (barrels, pipes, containers, facilities, etc.). We can provide: On-site measurements; Clearance measurements; Development and qualification of characterization methodologies and measuring equipment; Training and support for spectrum processing, use of measuring systems and modelling of objects to be characterized. Expertise and consultancy Based on our equipment and internationally recognized expertise, our unique team of experts provides private and public companies as well as international organizations with high level of consulting and technical services. We work in close collaboration with our clients and use all our resources to offer them a solution that meets their specific needs. Sources dismantling We provide comprehensive solutions for the dismantling of sealed radioactive sources to ensure that they are handled safely and appropriately. Our service includes characterization, dismantling and repackaging/conditioning. We have all necessary facilities for the dismantling of various types of sealed radioactive sources: smoke detectors, industrial and medical sources, lightning rods, orphan sources. Our team is also available to provide our expertise for the successful management of your spent sealed radioactive sources at your premises. ANALYSIS AND SERVICES For more information, consult our specific services brochure or email at bus@ire-elit.eu EXCELLENCE DEDICATED TO NUCLEAR MEDICINE, HEALTHCARE & ENVIRONMENT

WORK WITH US IS: Being determined to build a better FUTURE by contributing to public health and environmental protection. A FUTURE that provides access to the most effective healthcare thanks to the production of radioisotopes used in nuclear medicine for both diagnostic purposes (screening for cancerous tumours, analysis of the functioning of organs) and therapeutic purposes (treatment of cancers, palliative care). A FUTURE, too, in which the protection of the environment is a priority, thanks to the implementation of technologies for monitoring and measuring the radioisotopes naturally present in the soil, air and water. WE PUT OUR TRUST ONLY IN PARTNERS AND SUPPLIERS WHO SHARE OUR CONCERN FOR ETHICS AS A PRIORITY. At IRE- IRE ELiT we attach great importance to the human dimension of the business. The quality of social relations within the business is crucial, and aims to be based on transparency and mutual respect. We manage the business on the basis of five fundamental values: team spirit, innovation, responsibility, competence and partnership. Resolutely focused on the FUTURE, is it your vision of partnership and collaboration? So, let s start to talk! Avenue de l Espérance 1 B-6220 Fleurus Belgium T. +32 (0)71 82 95 96 F. +32 (0)71 81 38 12 www.ire.eu Follow us on IRE ELiT 2015

OUR HISTORY 1971 1973 1978 1979 1980 Creation of IRE and first constructions in Fleurus, Belgium Production of 131 I and 99 Mo. Creation of a radioimmunology department Creation of a 60 Co irradiation treatment unit First production of 123 I Construction of the first cyclotron Pharmaceutical recognition Creation of the concept for a repetitive elution 99m Tc dry generator Creation of a transport subsidiary: TRANSRAD 1990 1991 2000 Major investments in the context of the redeployment of radiopharmaceutical activities Development of equipment for the remote monitoring of environmental radioactivity and radiological monitoring missions within the Belgian territory Major investment by IBA on the Fleurus site (prototype 14 MeV SE cyclotron) 2008 2010 Expansion of international commercial activities (North America, Asia, etc.) Achievement of a leadership position in the production of 99 Mo et 131 I Creation of the IRE ELiT subsidiary Resumption of radiopharmaceutical activities in the diagnostic and therapy sectors ( 90 Y, 188 Re, 68 Ga, ) Launch of research partnerships worldwide Important IRE role in AIPES (Association of Imaging Producers & Equipment Suppliers) Major consultancy contracts worldwide (European Commission, IAEA, etc.)

Fleurus BELGIUM KEY FIGURES 27% USA MAIN MARKETS 6% South America & Middle East 53 % EU 14% Asia 95% PART OF IRE ACTIVITY FOR EXPORTATION 225 full-time NUMBER OF DIRECT JOBS PROVIDED BY THE BUSINESS IN FLEURUS INCREASE IN JOBS BETWEEN 2010 +53% 2015 INCREASE IN TURNOVER 2010 +140% 2015

A WORD FROM OUR CEO To lead such a company means, above all, being fully involved in the development of people, safety, ethics, autonomy and respect. It means encouraging our teams to keep on innovating to serve tens of thousands of patients who benefit from our products every day. Let us be ambitious, for ourselves and those patients health, and for the environment of our planet, because the only way not to lag behind is to stand in front. Jean-Michel Vanderhofstadt CEO IRE - IRE ELiT OUR MISSION The IRE, or Institute for Radioelements is a public utility foundation. Its main activity is the production of radioisotopes for diagnostic and treatment applications in nuclear medicine. These products are the active ingredients of many radiopharmaceutical medicines. For its part, IRE ELiT is a subsidiary of the IRE and produces several radiopharmaceutical derivatives used in the treatment of certain cancers and in palliative care. More than MILLION NUCLEAR MEDICINE EXAMINATIONS ARE CARRIED OUT EVERY YEAR THANKS TO THE MEDICAL RADIOISOTOPES PRODUCED BY THE IRE. In addition to its production activities, IRE ELiT contributes to the protection of the environment through its services activities focusing on radioactivity analysis in various samples, radiological characterization of waste and contaminated items, consultancy and technical assistance projects in the radiation and nuclear fields and sealed radioactive sources dismantling.

OUR VALUES In pursuing our mission, the management and personnel of IRE and its subsidiary IRE ELiT are committed to abiding by five key values that have each been broken down into attitudes and behaviours which are the references in the company s organization. COMPETENCE RESPONSIBILITY COMMITTED TO PARTNERSHIP INNOVATION TEAM SPIRIT Innovation Technological developments in the field of medical imaging and radiotherapy offer huge potential for IRE - IRE ELiT. This is a sector in which the company wishes to position itself and takes an active part in scientific and medical development. The same applies to the environmental sector. Responsiblity We have a responsibility to ensure that we give top priority at all times to safety/security, quality and the environment, in all the actions taken within the company and in all the decisions we make. This means that achieving production, economic and financial objectives, as well as adhering to objectives within projects, takes second place after safety and quality. Competence Maintaining a high level of requirement and quality of work, based on the professionalism and expertise of each member of our staff, is essential in the culture of IRE - IRE ELiT. Partnership In its relations with outside partners, IRE - IRE ELiT aims to create lasting and quality relationships based on high levels of ethics and loyalty. This client-focused and ethics-oriented dimension is key to adhering to its vision of internationally recognised excellence. Team spirit IRE - IRE ELiT manages a significant number of structured projects and multidisciplinary improvement action plans where teamwork is essential to the achievement of objectives with the required level of quality.